Pseudomyxoma Peritonei clinical trials at UCSF

1 research study open to eligible people

Pseudomyxoma Peritonei is a rare cancer that starts in the appendix. UCSF is recruiting for a clinical trial that will test a drug called SGN-STNV to see if it is safe for patients with solid tumors. The study will determine what side effects, if any, the drug may cause.

Showing trials for

  • A Study of SGN-STNV in Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

    San Francisco, California and other locations

Our lead scientists for Pseudomyxoma Peritonei research studies include .

Last updated: